Neuphoria Therapeutics shares rose 4.5% premarket after announcing a strategic review that could include mergers, acquisitions, or partnerships. The company also received a non-binding $5.20-per-share cash offer from Lynx1 Master Fund LP to acquire all outstanding shares it doesnt already own. Neuphoria said the review aims to advance its drug pipeline and maximise shareholder value.